Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;33(6):562-568.
doi: 10.1159/000540854. Epub 2024 Aug 12.

Serum Levels of Plasminogen Activator Inhibitor-1 in Patients with Parkinson's Disease

Azra Meryem Tanrikulu  1 , Betul Ozdilek  2   3 , Mehmet Agirbasli  4   5
Affiliations

Serum Levels of Plasminogen Activator Inhibitor-1 in Patients with Parkinson's Disease

Azra Meryem Tanrikulu et al. Med Princ Pract. 2024.

Abstract

Objectives: The aim of the study was to investigate serum plasminogen activator inhibitor-1 (PAI-1) levels of patients with Parkinson's disease (PD) and their relationship with clinical findings and treatment of disease.

Methods: The study included 125 PD patients and 48 healthy controls. Patients have been taking effective dopaminergic treatment regularly. The clinical severity of parkinsonism was assessed using the Hoehn and Yahr (HY) staging scale and the Unified PD Rating Scale (UPDRS). PAI-1 level analysis was performed by enzyme-linked immunosorbent assay.

Results: Patients with PD had significantly lower serum PAI-1 levels than healthy controls (p < 0.001). Correlations with clinical findings showed only a marginally positive correlation between serum PAI-1 and HY score (r = 0.170, p = 0.05). In contrast, no significant correlation was demonstrated with the UPDRS score or other clinical parameters.

Conclusion: This is the first comprehensive analysis of serum PAI-1 levels in patients with PD. The distribution of PAI-1 in PD appears to be complex. The study results implicate that the paradoxical effects of tissue plasminogen activator on the brain parenchyma can be important in the pathophysiology of PD. Future studies are needed to elucidate the role of fibrinolytic system components in PD.

Keywords: Neurodegeneration; PAI-1; Parkinson’s disease; Serum.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Fig. 1.
Fig. 1.
Scatter plot showing serum PAI-1 levels of patients with PD and healthy controls (p < 0.001).
Fig. 2.
Fig. 2.
Correlation analysis between serum PAI-1 levels and HY staging scores in patients with PD (Spearman’s correlation test, r = 0.170, p = 0.05).
See this image and copyright information in PMC

References

    1. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. . Parkinson disease. Nat Rev Dis Primers. 2017;3:17013. - PubMed
    1. Michel PP, Hirsch EC, Hunot S. Understanding dopaminergic cell death pathways in Parkinson disease. Neuron. 2016;90(4):675–91. - PubMed
    1. Simon DK, Tanner CM, Brundin P. Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med. 2020;36(1):1–12. - PMC - PubMed
    1. Johnson ME, Stecher B, Labrie V, Brundin L, Brundin P. Triggers, facilitators, and aggravators: redefining Parkinson’s disease pathogenesis. Trends Neurosci. 2019;42(1):4–13. - PMC - PubMed
    1. Nolan YM, Sullivan AM, Toulouse A. Parkinson’s disease in the nuclear age of neuroinflammation. Trends Mol Med. 2013;19(3):187–96. - PubMed

Substances